BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/23/2026 8:57:27 AM | Browse: 3 | Download: 10
 |
Received |
|
2026-07-28 08:13 |
|
Peer-Review Started |
|
2026-08-06 09:07 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2026-08-20 06:02 |
|
Revised |
|
2026-08-26 02:20 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-09-20 02:51 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-09-20 11:01 |
|
Articles in Press |
|
2026-09-20 11:01 |
|
Edit the Manuscript by Language Editor |
|
2026-09-22 01:03 |
|
Typeset the Manuscript |
|
2026-09-23 02:20 |
|
Publish the Manuscript Online |
|
2026-09-23 08:57 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Minireviews |
| Article Title |
Precision medicine in diffuse large B-cell lymphoma: Integrating molecular biomarkers, targeted therapies, and prognostic tools
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Bing-Ling Guo, Hai-Ke Lei and Yao Liu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yao Liu, Department of Hematology Oncology, Chongqing University Cancer Hospital, No. 181 HanYu Road, Chongqing 400030, China. liuyao77@cqu.edu.cn |
| Key Words |
Diffuse large B-cell lymphoma; Precision medicine; molecular biomarkers; Targeted therapy; prognostic models; ctDNA; Chimeric antigen receptor T-cell therapy; Genetic subtyping; Tumor microenvironment; Immunochemotherapy |
| Core Tip |
Diffuse large B-cell lymphoma (DLBCL) is a biologically heterogeneous disease requiring precision medicine approaches beyond standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy. This review synthesizes current evidence on integrating molecular subtyping (cell-of-origin and genetic subtypes), circulating tumor DNA monitoring, and tumor microenvironment characterization into clinical decision-making. We critically evaluate emerging targeted therapies including Bruton tyrosine kinase inhibitors, BCL-2 inhibitors, antibody-drug conjugates, bispecific T-cell engagers, and chimeric antigen receptor T-cell therapy. Prognostic models have evolved from the International Prognostic Index to dynamic, integrative nomograms incorporating molecular biomarkers. Challenges in standardization, cost-effectiveness, and equitable access are discussed alongside future directions for personalized DLBCL management. |
| Publish Date |
2026-09-23 08:57 |
| Citation |
Guo BL, Lei HK, Liu Y. Precision medicine in diffuse large B-cell lymphoma: Integrating molecular biomarkers, targeted therapies, and prognostic tools. World J Clin Oncol 2026; 17(9): 125602
|
| URL |
https://www.wjgnet.com/2218-4333/full/v17/i9/125602.htm |
| DOI |
https://doi.org/10.5306/wjco.125602 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
